Topical Tenofovir Disoproxil Fumarate (DF) Nanoparticles Prevents HIV-1 Vaginal Transmission in the Humanized Mouse Model.
Abstract
Pre-Exposure Prophylaxis (PrEP), 1% tenofovir (TFV) vaginal gel has failed in clinical trials. To improve TFV efficacy in vaginal gel, we formulated tenofovir disoproxil fumarate (TDF) nanoparticles (NPs) in a thermosensitive (TMS) gel (TDF-NPs-TMS gel). TDF NPs were fabricated using Poly Lactic-co-Glycolic Acid (PLGA) polymer and an ion-pairing agent by oil-in-water emulsification. Efficacy of TDF-NPs-TMS gel was tested in humanized-bone marrow-liver-thymus (BLT) (hu-BLT) mice.Hu-BLT mice grouped as treatment (Rx; n=15) were administered TDF-NPs-TMS gel intravaginally having TDF at 0.1%, 0.5%, an...
Source: Antimicrobial Agents and Chemotherapy - April 3, 2016 Category: Microbiology Authors: Destache CJ, Mandal S, Zhe Y, Kang G, Date AA, Lu W, Shibata A, Pham R, Bruck P, Rezich M, Zhou Y, Vivekanandan R, Fletcher CV, Li Q Tags: Antimicrob Agents Chemother Source Type: research
[Bacterial vaginosis: efficacy of a local treatment with a gel containing a fraction derived from propinibacterium acnes].
CONCLUSIONS: The activation of the vaginal immune system induced by Immunovag® can antagonize the symptoms of BV and counteract the growth of vaginal anaerobic microorganisms.
PMID: 26990097 [PubMed - as supplied by publisher] (Source: Minerva Ginecologica)
Source: Minerva Ginecologica - March 20, 2016 Category: OBGYN Tags: Minerva Ginecol Source Type: research
Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
Abstract
VOICE—a phase 2B, placebo-controlled, randomized trial testing daily use of an antiretroviral tablet (tenofovir or Truvada) or daily use of tenofovir gel in 5029 women from South Africa, Uganda, and Zimbabwe—found none of the drug regimens effective in reducing HIV-1 acquisition in the intent-to-treat analysis. More than half of women assigned to active products in a case cohort sample had no drug detected in any plasma specimens tested during the trial. Yet, in response to questions asked of participants during the trial, ≥90 % of doses were reportedly taken. To explore factors associated...
Source: AIDS and Behavior - February 23, 2016 Category: Infectious Diseases Source Type: research
Abstract P4-11-06: Feasibility of a non-hormonal vaginal moisturizer in postmenopausal cancer survivors
Conclusions:Preliminary findings suggest that an HLA vaginal gel may improve vaginal/sexual health issues and concerns of breast cancer survivors both in their perceived symptoms and on clinical exam; however, further study is needed to examine if these promising trends continue over time and to determine the ideal frequency of product administration.Citation Format: Carter J, Seidel B, Stabile C, Dickler M, Goldfrank D, Baser R, Goldfarb S. Feasibility of a non-hormonal vaginal moisturizer in postmenopausal cancer survivors. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Sympos...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Carter, J., Seidel, B., Stabile, C., Dickler, M., Goldfrank, D., Baser, R., Goldfarb, S. Tags: Poster Session Abstracts Source Type: research
Induction of labor using prostaglandin vaginal gel: cost analysis comparing early amniotomy with repeat prostaglandin gel
Conclusions After an initial dose of PGE2 vaginal gel, a policy of administering more PGE2 when the Modified Bishop's score is <7 was associated with increased healthcare costs compared with a policy of performing an amniotomy, if technically possible. Length of stay was the main driver of healthcare costs. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - February 11, 2016 Category: OBGYN Source Type: research
Induction of labor using prostaglandin vaginal gel: cost analysis comparing early amniotomy with repeat prostaglandin gel
In a randomized controlled trial of two policies for induction of labor (IOL) using Prostaglandin E2 (PGE2) vaginal gel, women who had an earlier amniotomy experienced a shorter IOL-to-birth time. (Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology)
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - February 11, 2016 Category: OBGYN Authors: Michael Beckmann, Katharina Merollini, Sailesh Kumar, Vicki Flenady Source Type: research
[Comment] Oral misoprostol is as safe as Foley catheter for labour induction…or is it?
In The Lancet, the researchers of the PROBAAT-II study1 pass another milestone on the long and circuitous evolution of methods to ripen the uterine cervix during induction of labour. Before there were prostaglandins, there were mechanical methods. One was a simple Foley catheter bulb passed through the cervix and inflated in the potential space between the amniotic sac and the uterus.2 In the decades following the introduction of dinoprostone vaginal gel, the Foley catheter method was all but forgotten. (Source: LANCET)
Source: LANCET - February 1, 2016 Category: Journals (General) Authors: G Justus Hofmeyr Tags: Comment Source Type: research
Endometrin/prometrium versus intramuscular progesterone administration for luteal phase support
The ideal method of endometrial preparation for a frozen embryo transfer (FET) is not defined1. Intramuscular (IM) progesterone has been the standard approach, but is uncomfortable and sometimes intolerable to patients. Alternative routes of progesterone administration include oral and vaginal. Oral progesterone is rapidly metabolized and is generally accepted to be inferior to the IM or vaginal route1-4. Several studies comparing outcomes of progesterone vaginal gel (Crinone®) vs. IM have shown mixed results2-5. (Source: Fertility and Sterility)
Source: Fertility and Sterility - January 29, 2016 Category: Reproduction Medicine Authors: Reem Sabouni, Daniel B. Williams, Jason Griffith, Ghassan Haddad, Wei-Hua Wang, Craig A. Witz Tags: Poster Presentation Source Type: research
The G-spot: an observational MRI pilot study.
CONCLUSIONS: There is evidence for an in vivo morphological correlate to the postmortem anatomical findings of a GSC described by Ostrzenski et al.; its visibility in MRI imaging can be significantly improved with vaginal opacification by ultrasound gel.
TWEETABLE ABSTRACT: Identification of G-spot by MRI with vaginal gel-opacification in 13/21 patients.
PMID: 26776843 [PubMed - as supplied by publisher] (Source: BJOG : An International Journal of Obstetrics and Gynaecology)
Source: BJOG : An International Journal of Obstetrics and Gynaecology - January 18, 2016 Category: OBGYN Authors: Maratos YK, Gombergh R, Cornier E, Minart JP, Amoretti N, Mpotsaris A Tags: BJOG Source Type: research
The G‐spot: an observational MRI pilot study
ConclusionsThere is evidence for an in vivo morphological correlate to the postmortem anatomical findings of a GSC described by Ostrzenski et al.; its visibility in MRI imaging can be significantly improved with vaginal opacification by ultrasound gel.
Tweetable abstractIdentification of G‐spot by MRI with vaginal gel‐opacification in 13/21 patients. (Source: BJOG: An International Journal of Obstetrics and Gynaecology)
Source: BJOG: An International Journal of Obstetrics and Gynaecology - January 18, 2016 Category: OBGYN Authors: YK Maratos, R Gombergh, E Cornier, JP Minart, N Amoretti, A Mpotsaris Tags: Original Article Source Type: research
The G ‐spot: an observational MRI pilot study
ConclusionsThere is evidence for an in vivo morphological correlate to the postmortem anatomical findings of a GSC described by Ostrzenski et al.; its visibility in MRI imaging can be significantly improved with vaginal opacification by ultrasound gel.
Tweetable abstractIdentification of G‐spot by MRI with vaginal gel‐opacification in 13/21 patients. (Source: BJOG: An International Journal of Obstetrics and Gynaecology)
Source: BJOG: An International Journal of Obstetrics and Gynaecology - January 17, 2016 Category: OBGYN Authors: YK Maratos, R Gombergh, E Cornier, JP Minart, N Amoretti, A Mpotsaris Tags: Psychosexual health Source Type: research
Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
CONCLUSIONS: Identifying an effective microbicide that women can use consistently is vital to the future of HIV prevention for women. Once such a microbicide is identified and licensed, positioning, marketing and delivering microbicides in a way that takes into account the gendered norms and inequalities we have identified would help maximize access and adherence. It also has the potential to improve communication about sexuality, strengthen relationships between women and men and increase women's agency over their bodies and their health.
PMID: 26700845 [PubMed - as supplied by publisher] (Source: Journal of the I...
Source: Journal of the International AIDS Society - December 26, 2015 Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel
This study aims to evaluate the sexual function and quality of life (QoL) of naturally postmenopausal women affected by genitourinary syndrome of menopause who were treated with an ultralow-concentration estriol vaginal gel (0.005%).
Methods: Postmenopausal women with vulvovaginal atrophy symptoms and sexual disorders were enrolled in a case-control study. Women were treated with vaginal gel (containing 50 μg of estriol) daily for 3 weeks and then twice weekly up to 12 weeks. Determination of vaginal maturation index, evaluation of vaginal pH, and assessment of vaginal atrophy symptoms were carried out. QoL, sexual func...
Source: Menopause - December 23, 2015 Category: OBGYN Tags: Original Articles Source Type: research
Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial
Conclusions. Oral TDF modestly decreased HSV shedding and lesion rate, and quantity of virus shed when used consistently. Vaginal TFV gel decreased quantity of virus shed by 60%. In contrast to effects on HSV-2 acquisition, tenofovir is unlikely to provide clinically meaningful reductions in the frequency of HSV shedding or genital lesions.
Clinical Trials Registration. NCT01448616 (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - November 23, 2015 Category: Infectious Diseases Authors: Bender Ignacio, R. A., Perti, T., Magaret, A. S., Rajagopal, S., Stevens, C. E., Huang, M.-L., Selke, S., Johnston, C., Marrazzo, J., Wald, A. Tags: VIRUSES Source Type: research
Willingness to participate in future HIV prevention trials in Beira, Mozambique.
Authors: Meque I, Dubé K, Bierhuizen L, Zango A, Veldhuijzen N, Cumbe F, Feldblum PJ, van de Wijgert J
Abstract
In preparation for trials of new HIV prevention methods, willingness to participate (WTP) was assessed in Beira, Mozambique. A total of 1 019 women participating in an HIV incidence study, and 97 men participating in a separate WTP survey, were interviewed. When comparing the answers to questions that were identical in the two studies, WTP was higher among women than men for all prevention methods. Among women, WTP was highest for trials evaluating daily oral pre-exposure prophylaxis (PrEP; 84.4...
Source: African Journal of AIDS Research - November 20, 2015 Category: African Health Tags: Afr J AIDS Res Source Type: research
